Compare AX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | MIRM |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.7B |
| IPO Year | 2004 | 2019 |
| Metric | AX | MIRM |
|---|---|---|
| Price | $94.25 | $94.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $103.14 | ★ $119.00 |
| AVG Volume (30 Days) | 311.6K | ★ 545.3K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $65,789,000.00 | $19,138,000.00 |
| Revenue This Year | $24.76 | $26.22 |
| Revenue Next Year | $10.86 | $22.04 |
| P/E Ratio | $23.76 | ★ N/A |
| Revenue Growth | ★ 1.78 | N/A |
| 52 Week Low | $62.35 | $40.00 |
| 52 Week High | $101.92 | $109.28 |
| Indicator | AX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 50.18 |
| Support Level | $90.96 | $85.35 |
| Resistance Level | $100.44 | $98.03 |
| Average True Range (ATR) | 2.72 | 3.25 |
| MACD | 0.13 | -0.32 |
| Stochastic Oscillator | 45.19 | 44.20 |
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.